Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus bevacizumab for high-risk multiple ground-glass nodules in synchronous stage I non-small cell lung cancer
ChiCTR2100045164Phase 2Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: Safety and tolerability. Planned start Mar 2021; status: not yet recruiting.
02
Drugs
sintilimabbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100045164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045164.